FindTrial
Sign In

A prospective, randomized, controlled tial of recombinant FSH combined with HP-HMG on ovarian response and clinical outcomes

A prospective, randomized, controlled tial of recombinant FSH combined with HP-HMG on ovarian response and clinical outcomes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004965
Enrollment
Unknown
Registered
2014-06-22
Start date
2014-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

A:recombinant FSH
B:r-FSH combine HP-HMG

Sponsors

Maternal and Children Health Care Hospital of Shaanxi Provence
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. To be aged 20-38 years; 2. AFC more than 7; 3. Base FSH less than 1010mIU/ml; 4. The frist cycle for IVF/ICSI; 5. Luteal phase aganist long protocol.

Exclusion criteria

Exclusion criteria: 1. The endometriosis; 2. The uterine adenomyosis; 3. The uterine cavity abnormal, include septate uterus, unicornuate uterus, bicornuate uterus, didelphic uterus. intrauterine adhesions, submucosal uterine fibroids; 4. Contraindications to assisted reproductive technology and pregnancy.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate per translate cycle;Live birth rate per translate cycle;average oocytes retrieved;number of top quality embry;—

Countries

China

Contacts

Public ContactJuanzi SHI
shijuanzi@126.com+86 18602991568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026